Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke
- 382 Downloads
Given that alteplase has been the only approved thrombolytic agent for acute ischemic stroke for almost two decades, there has been intense interest in more potent and safer agents over the last few years. Tenecteplase is a bioengineered mutation of alteplase with advantageous pharmacodynamics and pharmacokinetics. The superiority of tenecteplase over alteplase has been proven by in vitro and animal studies, and it was approved for use in myocardial infarction more than a decade ago. In patients with acute ischemic stroke, tenecteplase has shown promise in randomized phase II trials and the drug is currently being tested in four phase III clinical trials that will start delivering definite results in the near future: NOR-TEST (NCT01949948), TASTE (ACTRN12613000243718), TEMPO-2 (NCT02398656), and TALISMAN (NCT02180204).
KeywordsIschemic Stroke Acute Ischemic Stroke Alteplase Stroke Onset Mechanical Thrombectomy
Compliance with Ethical Standards
Authors did not received any funding for the preparation of this manuscript.
Conflicts of Interest
NL is the principal investigator of the NOR-TEST study. CEK is a member of the NOR-TEST executive working group. LT is the study chair of the NOR-TEST study. NOR-TEST is an investigator-driven academic trial with no connections to pharmaceutical companies. NOR-TEST is supported by a 3-year grant from the Norwegian Research Council (Project No. 229006).
- 1.Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–102.CrossRefPubMedGoogle Scholar
- 5.Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gronning BA, et al. Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575–84.CrossRefPubMedGoogle Scholar
- 10.Huang X, Fulton R, Parsons M, Levi C, Campbell B, Bladin C, Haley E, Thompson JLP, Levin B, Buchsbaum R, Muir KW, Tenecteplase versus Alteplase in acute ischaemic stroke thrombolysis: a meta-analysis of individual patient data from randomised studies. Abstract - oral presentation. 1st ESO conference, Glasgow, April 17-19, 2015Google Scholar
- 12.Parsons M. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363714. Accessed 27 May 2015.
- 13.Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther. 2001;23(7):982–97 (discussion 981).Google Scholar
- 17.Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72(1):98–104.PubMedGoogle Scholar
- 18.Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994;25(10):2072–8 (discussion 2078–9).Google Scholar
- 20.Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98(25):2805–14.Google Scholar
- 21.Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999;137(5):786–91.CrossRefPubMedGoogle Scholar
- 22.Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716–22.Google Scholar
- 24.Molina CA, Ribo M, Rubiera M, Santamarina E, Delgado-Mederos R, Maisterra O, et al. TNK induces faster MCA recanalization and leads to better short- and long-term clinical outcome than native tPA. The TNK-TPA Reperfusion Stroke Study [abstract]. Stroke. 2008;39(2):563.Google Scholar